Zymeworks Inc. ZYME

US Biotechnology

$31.31 ▲ +1.62% (+$0.50)

⬆️ Above Yest. High

Open $31.04

Prev Close $30.81

Day Range $30.64 – $31.98

52W Range $16.00 – $31.49

Market Cap $2.02B

Beta 1.37

EPS (TTM) $-2.01

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-06-24
Shares Out.	70,480,000
Website	zymeworks.com ↗
Phone	13022748744
Employees	264
Revenue	$4.6M
Gross Profit	$4.6M
Net Income	-$45.0M
Free Cash Flow	-$120.5M
Total Assets	$397.0M
Total Liabilities	$316.6M
Equity	$80.4M

About Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks Inc. is a publicly traded company under the ticker symbol ZYME on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.